Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.38 |
| ▸ | PDE2A | O00408 | 11/20 | 0.37 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
| ▸ | CBFB | Q13951 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066026 | 0.89 | PDE2A (0.37) | SCN10APDE2AGPR139 | |
| SCHEMBL12066028 | 0.88 | PDE2A (0.36) | SCN10APDE2A | |
| SCHEMBL14763244 | 0.88 | PDE2A (0.36) | SCN10APDE2A | |
| SCHEMBL12065647 | 0.85 | SCN10A (0.40) | SCN10APDE2ACYP3A4 | |
| SCHEMBL14763411 | 0.82 | FFAR1 (0.39) | — | |
| SCHEMBL12065287 | 0.82 | SCN10A (0.36) | SCN10APDE2AGPR139 | |
| SCHEMBL12065251 | 0.82 | MLKL (0.38) | SCN10APDE2AGPR139 | |
| SCHEMBL12065313 | 0.81 | FFAR1 (0.42) | — | |
| SCHEMBL12066025 | 0.81 | SCN10A (0.45) | SCN10APDE2ACBFBCYP3A4 | |
| SCHEMBL12066012 | 0.80 | MEN1 (0.45) | SCN10APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | claimed |
| EP-2578573-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA Eiyo Ltd. (JP) | 2013-04-10 | — | — | EP | claimed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | claimed |
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| EP-2578573-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA Eiyo Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| WO-2011148956-A1 | FUSED IMIDAZOLE DERIVATIVE | トーアエイヨー株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | SCN10A 85/4885PDE2A 1306/4885GPR139 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.